Avalo Therapeutics (AVTX) Common Equity (2014 - 2026)

Avalo Therapeutics (AVTX) has 13 years of Common Equity data on file, last reported at $68.3 million in Q1 2026.

• Quarterly Common Equity fell 44.28% year-over-year to $68.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $68.3 million (down 44.28% YoY) and the FY2025 annual result came in at $83.0 million, down 37.57% from the prior year.
• Common Equity retreated to $68.3 million in Q1 2026, from $83.0 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $133.0 million in Q4 2024 to a low of -$112.5 million in Q1 2024.
• A 5-year average of $29.1 million and a median of $7.3 million in 2023 frame the typical range for Common Equity.
• The widest YoY moves for Common Equity: up 1721.36% in 2024, down 1695.79% in 2024.
• Tracing AVTX's Common Equity over 5 years: stood at -$10.9 million in 2022, then surged by 166.92% to $7.3 million in 2023, then surged by 1721.36% to $133.0 million in 2024, then slumped by 37.57% to $83.0 million in 2025, then slipped by 17.74% to $68.3 million in 2026.
• The last three Common Equity figures came in at $68.3 million (Q1 2026), $83.0 million (Q4 2025), and $91.5 million (Q3 2025), per Business Quant data.